Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-07-26
2000-09-12
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
549 16, 549 17, 549359, 549392, 549 27, 544347, 544348, 544 581, 544104, 546103, 548504, 5483351, 514297, 5142278, 5142275, 5142298, 514415, 514396, 514434, 514452, 514454, 514437, 51425505, 51425506, 562427, C07D32708, C07D33908, C07D31182, A61K 3139, A61K 31385
Patent
active
061178691
ABSTRACT:
The present invention relates to compounds of Formula I that inhibit matrix metalloproteinases and to a method of inhibiting matrix metalloproteinases using the compounds ##STR1## More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilatation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
REFERENCES:
patent: 4066773 (1978-01-01), Okamoto et al.
Sato H., et al., "A matrix metalloproteinase expressed on the surface of invasive tumour cells", Nature, vol. 370, 1994, pp 61-65.
Galis Z. S., et al., "Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques", J. Clin. Invest., vol. 94, 1994, pp 2494-2503.
Henney A. M., et al., "Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization", Proc. Natl. Acad. Sci. U.S.A., vol. 88, 1991, pp 8154-8158.
Vine and Powell, "Metalloproteinases in degenerative aortic diseases", Clin. Sci., vol. 81, 1991, pp 233-239.
Lee T. H., et al., "Impact of left ventricular cavity size on survival in advanced heart failure", Am. J. Cardiol., vol. 72, 1993, pp 672-676.
Reddy H. K., et al., "Activated myocardial collagenase in idiopathic dilated cardiomyopathy: a marker of dilatation and remodeling", Clin. Res, vol. 41, No. 3, 1993, p 660A.
Tyagi S. C., et al., "Myocardial collagenase in failing human heart", Clin. Res., vol. 41, No. 3, 1993, p 681 A.
Armstrong P. W., et al., "Structural remodelling in heart failure: gelatinase induction", Can J. Cardiol., vol. 10, No. 2, 1994, pp 214-220.
Sabbah H. N., et al., "Left ventricular shape changes during the course of evolving heart failure", Am. J. Physiol., vol. 263, 1992, pp H266-H270.
Bendeck M. P., et al., "Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat", Circulation Research, vol. 75, No. 3, 1994, pp 539-545.
Pauly R. R., et al., "Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation", Circulation Research, vol. 75, No. 1, 1994, pp 41-54.
Davies M., et al., "Proteinases and glomerular matrix turnover", Kidney Int., vol. 41, 1992, pp 671-678.
Martin J., et al., "Enhancement of glomerular mesangial cell neutral proteinase secretion by macrophages: role of interleukin 1", J Immunol., vol. 137, No. 2, 1986, pp 525-529.
Marti H. P., et al., "Homology cloning of rat 72 kDa type IV collagenase: cytokine and second-messenger inducibility in glomerular mesangial cells", Biochem. J., vol. 291, 1993, pp 441-446.
Marti H. P., et al., "Transforming growth factor-.beta.1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase", Am. J. Pathol., vol. 144, No. 1, 1994, pp 82-94.
Bagchus W. M., et al., "Glomerulonephritis induced by monoclonal anti-thy 1.1 antibodies: A sequential histological and ultrastructural study in the rat", Lab. Invest., vol. 55, No. 6, 1986, pp 680-687.
Lovett D. H., et al., "Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex mediated glomerulonephritis" Am. J. Pathol., vol. 141, No. 1, 1992, pp 85-98.
Brown P. D., et al., "Independent expression and cellular processing of M.sub.r 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines", Cancer Res., vol. 50, 1990, pp 6184-6191.
Kitamura M., et al., "Gene transfer of metalloproteinase transin induces aberrant behavior of cultured mesangial cells", Kidney Int., vol. 45, 1994, pp 1580-1586.
Turck J., et al., "Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation", J. Biol. Chem., vol. 271, No. 25, 1996, pp 15074-15083.
Uitto V. J., et al., "Collagenase and neutral metallo-proteinase activity in extracts of inflamed human gingiva", J. Periodontal Res., vol. 16, 1981, pp 417-424.
Overall C. M., et al., "Demonstration of tissue collagenase activity in vivo and its relationship to inflammation severity in human gingiva", J. Periodontal Res., vol. 22, 1987, pp 81-88.
Brown S. I., et al., "Collagenolytic activity of alkali-burned corneas", Arch. Ophthal., vol. 81, 1969, pp 370-373.
Burns F. R., et al., "Inhibition of purified collagenase from alkali-burned rabbit corneas", Invest. Ophthalmol., vol. 30, No. 7, 1989, pp 1569-1575.
Saarialho-Kere U. K., et al., "Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds", J. Clin. Invest., vol. 94, 1994, pp 79-88.
Davies B., et al., "A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts", Cancer Res., vol. 3, 1993, pp 2087-2091.
Melchiori A., et al., "Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment", Cancer Res., vol. 52, 1992, pp 2353-2356.
DeClerck Y. A., et al., "Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases", Cancer Res., vol. 52, 1992, pp 701-708.
Strongin A. Y., et al., "Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2*", J. Biol. Chem., vol. 268, No. 19, 1993, pp 14033-14039.
Monsky W. L., et al., "Binding and localization of M.sub.r 72,000 matrix metalloproteinase at cell surface invadopodia", Cancer Res., vol. 53, 1993, pp 3159-3164.
Taraboletti G., et al., "Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases", Journal of the National Cancer Institute, vol. 87, No. 4, 1995, pp 293-298.
Benelli R., et al., "Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy", Oncology Research, vol. 6, No. 6, 1994, pp 251-257.
Walakovits L. A., et al., "Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and post-traumatic knee injury", Arthritis Rheum., vol. 35, No. 1, 1992, pp 35-42.
Zafarullah M., et al., "Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia", J. Rheumatol., vol. 20, No. 4, 1993, pp 693-697.
Andrews H. J., et al., "A synthetic peptide metalloproteinase inhibitor, but not Timp, prevents the breakdown of proteoglycan within articular cartilage in vitro", Agents Actions, vol. 37, 1992, pp 147-154.
Ellis A. J., et al., "The prevention of collagen breakdown in bovine nasal cartilage by Timp, Timp-2 and a low molecular weight synthetic inhibitor", Biochem. Biophys. Res. Commun., vol. 201, No. 1, 1994, pp 94-101.
Gijbels K., et al., "Reversal of Experimental Autoimmune Encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases", J. Clin. Invest., vol. 94, 1994, pp 2177-2182.
Romanic and Madri, " The induction of 72-kD Gelatinase in T cells upon adhesion of Endothelial cells is VCAM-1 Dependent", J. Cell Biology, vol. 125, No. 5, 1994, pp 1165-1178.
Picard Joseph Armand
Roth Bruce David
Sliskovic Drago Robert
Ashbrook Charles W.
Liu Hong
Raymond Richard L.
Warner-Lambert & Company
LandOfFree
Compounds for and methods of inhibiting matrix metalloproteinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for and methods of inhibiting matrix metalloproteinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for and methods of inhibiting matrix metalloproteinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96375